

IN THE CLAIMS:

1-47 (Presently Canceled)

sub. >

48. (New): An isolated polypeptide selected from the group consisting of:

a) a polypeptide which is encoded by a nucleic acid molecule comprising a nucleotide sequence which is at least 90% identical to the nucleotide sequence of SEQ ID NO:45 or SEQ ID NO:46;

b) a polypeptide which is encoded by a nucleic acid molecule comprising a nucleotide sequence which is at least 90% identical to the nucleotide sequence of clone EpT294, which was deposited with ATCC as Accession Number 207220;

c) a polypeptide which is at least 90% identical to the amino acid sequence of SEQ ID NO:47;

d) a polypeptide which is at least 90% identical to residues 15-423 of the amino acid sequence of SEQ ID NO:47; and

e) a polypeptide which is at least 90% identical to the amino acid sequence of SEQ ID NO: 49;

wherein the polypeptide exhibits a lipase activity.

2

49. (New): The isolated polypeptide of claim 48, wherein the polypeptide is encoded by a nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the nucleotide sequence of SEQ ID NO:45 or SEQ ID NO:46.

sub. >

50. (New): The isolated polypeptide of claim 48, wherein the polypeptide is encoded by a nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the nucleotide sequence of clone EpT294, which was deposited with ATCC as Accession Number 207220.

4 ¹
51. (New): The isolated polypeptide of claim 48, wherein the polypeptide is at least 95% identical to the amino acid sequence of SEQ ID NO:47.

5 ¹
52. (New): The isolated polypeptide of claim 48, wherein the polypeptide is at least 95% identical to residues 15-423 of the amino acid sequence of SEQ ID NO:47.

6 ¹
53. (New): The isolated polypeptide of claim 48, wherein the polypeptide is at least 95% identical to the amino acid sequence of SEQ ID NO:49.

54. (New): The isolated polypeptide of claim 48, having the amino acid sequence of SEQ ID NO:47.

55. (New): The isolated polypeptide of claim 48, having the amino acid sequence of SEQ ID NO:49.

7 ¹
56. (New): The isolated polypeptide of claim 48, wherein the amino acid sequence of the polypeptide further comprises heterologous amino acid residues.

8 ¹
57. (New): The isolated polypeptide of claim 48, admixed with a pharmaceutically acceptable carrier.

9 ¹
58. (New): An isolated polypeptide which is encoded by a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:45 or SEQ ID NO:46.

10 ⁹
59. (New): The isolated polypeptide of claim 58, wherein the amino acid sequence of the polypeptide further comprises heterologous amino acid residues.

11 ⁹
60. (New): The isolated polypeptide of claim 58, admixed with a pharmaceutically acceptable carrier.

¹²
~~61.~~ (New): An isolated polypeptide which is encoded by the nucleotide sequence of the DNA insert of clone EpT294, which was deposited with ATCC as Accession Number 207220.

¹³ ¹²
~~62.~~ (New): The isolated polypeptide of claim ~~61~~, wherein the amino acid sequence of the polypeptide further comprises heterologous amino acid residues.

¹⁴ ¹²
~~63.~~ (New): The isolated polypeptide of claim ~~61~~, admixed with a pharmaceutically acceptable carrier.

¹⁵
~~64.~~ (New): An isolated polypeptide comprising the amino acid sequence of SEQ ID NO:47.

¹⁶ ¹⁵
~~65.~~ (New): The isolated polypeptide of claim ~~64~~, wherein the amino acid sequence of the polypeptide further comprises heterologous amino acid residues.

¹⁷ ¹⁵
~~66.~~ (New): The isolated polypeptide of claim ~~64~~, admixed with a pharmaceutically acceptable carrier.

¹⁸
~~67.~~ (New): An isolated polypeptide comprising the amino acid sequence of SEQ ID NO:49.

¹⁹ ¹⁸
~~68.~~ (New): The isolated polypeptide of claim ~~67~~, wherein the amino acid sequence of the polypeptide further comprises heterologous amino acid residues.

²⁰ ¹⁸
~~69.~~ (New): The isolated polypeptide of claim ~~67~~, admixed with a pharmaceutically acceptable carrier.